

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	10/721,774	11/26/2003	Christer Nordstedt	50291/016003	6338
	21559 CLARK & ELI	7590 02/15/2007 BING LLP		EXAMINER	
	101 FEDERAL BOSTON, MA			BORIN, MICHAEL L	
	boston, MA	02110		ART UNIT	PAPER NUMBER
				1631	
				MAIL DATE	DELIVERY MODE
				02/15/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.	Applicant(s)		
10/721,774	NORDSTEDT ET AL.		
Examiner	Art Unit		
Michael Borin	1631		

Advisory Action	10/721,774 NORDSTEDT ET AL.						
Before the Filing of an Appeal Brief	Examiner	Art Unit	_				
	Michael Borin	1631					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address					
HE REPLY FILED 16 January 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
a) The period for reply expiresmonths from the mailing d b) The period for reply expires on: (1) the mailing date of this Advi event, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b). MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f) Extensions of time may be obtained under 37 CFR 1.136(a). The date on the been filed is the date for purposes of determining the period of extension at CFR 1.17(a) is calculated from: (1) the expiration date of the shortened state above, if checked. Any reply received by the Office later than three months earned patent term adjustment. See 37 CFR 1.704(b).	sory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of ONLY CHECK BOX (b) WHEN THE FILL. which the petition under 37 CFR 1.136(a) and the corresponding amount of the fee. tutory period for reply originally set in the	the final rejection. RST REPLY WAS FILED WITHIN TV and the appropriate extension fee hav The appropriate extension fee under 3 final Office action; or (2) as set forth in	VO ⁄e 7				
NOTICE OF APPEAL 2. The Nation of Appeal was filed as: A brief in serve	Nianas with 27 CED 44 27 mount ha	Elad mikhim kum masukha sekha d	_4 -				
 The Notice of Appeal was filed on A brief in composition of filing the Notice of Appeal (37 CFR 41.37(a)), or any expenses a Notice of Appeal has been filed, any reply must bandenders. 	tension thereof (37 CFR 41.37(e))	, to avoid dismissal of the appea					
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief	, will <u>not</u> be entered because					
(a) They raise new issues that would require further consideration and/or search (see NOTE below);							
 (b) ☐ They raise the issue of new matter (see NOTE belo (c) ☐ They are not deemed to place the application in bet 		duaina ar simulificina the issues	£				
appeal; and/or	ter form for appear by materially re	ducing or simplifying the issues	ior				
(d) ☐ They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.					
4. The amendments are not in compliance with 37 CFR 1.1		empliant Amendment (PTOL-324	l).				
 Applicant's reply has overcome the following rejection(s) 							
 Newly proposed or amended claim(s) would be all the non-allowable claim(s). 	llowable if submitted in a separate,	timely filed amendment canceling	ng				
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows:	☐ will not be entered, or b) ☐ wivided below or appended.	Il be entered and an explanation	of				
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE		·					
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and and was not earlier presented. See 37 CFR 1.116(e). 	It before or on the date of filing a N d sufficient reasons why the affidat	otice of Appeal will <u>not</u> be entered it or other evidence is necessary	ed /				
The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. 🗌 The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.							
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s).						
13. Other:							
	Man	Michael Borin, Ph.D. Primary Examiner Art Unit: 1631					

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant's arguments are not deemed persuasive for the following reasons: Applicant argues that specification provides support for the subject matter being now claimed, namely inhibition of polymerization of amyloid peptide by particular peptides. However, at best, the specification discusses general probability that a compound that binds amyloid peptide will be capable of inhibiting aggregation of amyloid peptide and thus, the fybril formation. However, there is no consensus that any compound that is capable of binding to amyloid peptide is similarly capable of inhibiting amyloid peptide aggregation, and specification does not provide support that the particular peptides, as now claimed, do indeed inhibit amyloid peptide polymerization. The rejection is maintained.

MICHAEL BORIN, PH.D PRIMARY EXAMINER